ArticleVaccine2010
Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 75 citations in OpenAlex.
- Ocular toxoplasmosis: susceptibility in respect to the genes encoding the KIR receptors and their HLA class I ligands.Scientific reports · 2016Trial
- T-cell activation of Toxoplasma gondii positive donors by maltodextrin nanoparticles formulated with killed Toxoplasma gondii.BMC infectious diseases · 2025Article
- Structural Prediction and Antigenic Analysis of ROP18, MIC4, and SAG1 Proteins to Improve Vaccine Design againstInfectious disorders drug targets · 2025Article
- In silico identification and ex vivo evaluation of Toxoplasma gondii peptides restricted to HLA-A*02, HLA-A*24 and HLA-B*35 alleles in human PBMC from a Colombian population.Medical microbiology and immunology · 2024Article
- Human T-cell activation withLife science alliance · 2024Article
- CD4Vaccines · 2023Article
- Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances "Take a Village".Current pediatrics reports · 2022Review
- Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview.Current pediatrics reports · 2022Review
- A Novel Combined DNA Vaccine Encoding Toxoplasma gondii SAG1 and ROP18 Provokes Protective Immunity Against a Lethal Challenge in Mice.Acta parasitologica · 2021Article
- Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice.Scientific reports · 2020Article
- Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis.BMC infectious diseases · 2020Article
- iTRAQ-based Quantitative Proteomics Analysis Identifies Host Pathways Modulated duringMicroorganisms · 2020Article
- Review
- Key Limitations and New Insights Into theFrontiers in cellular and infection microbiology · 2020Review
- Assessment of DNA vaccine encodingIranian journal of basic medical sciences · 2019Article
- Immunogenicity of a Virus-Like-Particle Vaccine Containing Multiple Antigenic Epitopes ofFrontiers in immunology · 2019Article
- An Overview of Peripheral Blood Mononuclear Cells as a Model for Immunological Research ofFrontiers in cellular and infection microbiology · 2019Review
- Genetic Polymorphisms in Cytokine Genes in Colombian Patients with Ocular Toxoplasmosis.Infection and immunity · 2018Article
- Prospects on the Use ofFrontiers in microbiology · 2018Review
- Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.Scientific reports · 2017Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 7 institutions in 4 countries.
Funding
Abstract
Toxoplasma gondii is an intracellular parasite that causes severe neurologic and ocular disease in immune-compromised and congenitally infected individuals. There is no vaccine protective against human toxoplasmosis. Herein, immunization of L(d) mice with HF10 (HPGSVNEFDF) with palmitic acid moieties or a monophosphoryl lipid A derivative elicited potent IFN-gamma production from L(d)-restricted CD8(+) T cells in vitro and protected mice. CD8(+) T cell peptide epitopes from T. gondii dense granule proteins GRA 3, 6, 7, and Sag 1, immunogenic in humans for HLA-A02(+), HLA-A03(+), and HLA-B07(+) cells were identified. Since peptide repertoire presented by MHC class I molecules to CD8(+) T cells is shaped by endoplasmic reticulum-associated aminopeptidase (ERAAP), polymorphisms in the human ERAAP gene ERAP1 were studied and associate with susceptibility to human congenital toxoplasmosis (p<0.05). These results have important implications for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.